The FDA announces changes for who's eligible for the COVID-19 vaccine. Plus, should musicians shut up & sing or tell critics to kick rocks? A PR guru weighs in

The FDA announced a policy shift for COVID-19 vaccine approvals to focus on Americans considered high-risk of contracting the virus, and those older than age 65.

COVID-19 shots for healthy younger adults and children will no longer be routinely approved under a major new policy shift unveiled Tuesday by the Trump administration.

For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.

Kennedy’s FDA approved the use of the Novavax Covid-19 vaccine, but with strict conditions. It will only be made available to older people and those over the age of 12 with at least one medical condition that leaves them at high risk from Covid, The New York Times reported.

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the development of the company’s Covid-19 vaccine was purposefully delayed until after the 2020 presidential election.

Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to adults over 65 and people who are high risk. The move is a significant shift

Biopharmaceutical company BioNTech has announced funding of up to £1 billion into the UK over the next 10 years. The planned investment would be one of the biggest in the history of UK life sciences, the Department for Science, Innovation and Technology said.